Screening


assay modules to support development of bio- therapeutic and pharmaceutical products for use on the company’s Octet® instrumentation plat- form, for high-sensitivity protein quantitation and small molecule and fragment screening, respectively. The new modules are available via software upgrades and will enable, for the first time, life science researchers who require these capabilities to access the high-throughput, ease- of-use and cost-effectiveness of ForteBio’s leading label-free technology.


“The Octet® RED384 and Octet® QK384 will deliver revolutionary efficiency improvements for life science research applications that have tradi- tionally been conducted using ELISA or SPR-based methods,” says Silva. “For example, our new label- free instruments enable researchers to perform pro- tein kinetic screening and characterisation on a 384-well plate in about two hours.” The new high-sensitivity assay module can detect subnanogram per milliliter levels of analytes in quantitation mode. “For protein quantitation, life science researchers have traditionally run fluo-


rescence and luminescence ELISA methods to achieve greater sensitivity in their assays. Now, using ForteBio’s new modules, they can obtain highly precise results, enabling follow-up research to be conducted the same day,” says Silva. “Additionally, labs that have transitioned from ELISA techniques to the Octet® platform have improved their productivity by 50-70%, with no additional cost per well.”


Benefits of label-free technology “The trend towards biologically relevant assays is a large opportunity for label-free technologies,” says Gallant. “Scientists are able to study not only endogenous receptors in cell lines, but also primary cell types – both of which deliver access to recep- tors in more natural states. We have found that as scientists become more comfortable with technolo- gies that measure and interpret whole cell respons- es, they discover the greater power of the data gen- erated, especially when compared to single point/single pathway assays. Though the data out- put may seem initially more complex, it is also


 


  


  


 


LABEL-FREE HIGHTHROUGHPUT DIREC QUANTITATTATION D DIRECT QUANTITATION


Sub-ng/mL protein quantitation, IgG titer, HIS-tagged proteins, residual Protein A and low-affinity anti-drug antibody detection assays


DIPIP AND READ SIMPLICIT AFFORDABILIT AFFORDABILITY


SPR-qua ity data at a fraction of the cost, disposab e biosensorswith option al biosensor regeneration and re-racking deliver lowest cost per data point


Make your labmore productive by visitingwww.fortebio.com, or call 800-OCTE


ET-QK to request a demonstration in your lab Fa 46 Fast. a t. ast. Accurate EASY c at te. EASY EA A Y. Drug Discovery World Winter 2010/11


As always, our forte: real-time analysis of protein, smallmolecules and fragments in crudemixtures and in the presence of DMSO


AND READ SIMPLICITY fo


LABEL-FREE HIGH THROUGHPUT


Octet RED384 andOctetQK384 support two 384- or 96-well plates, and provide 16-wel simultaneous read-out fofor kon, koff, DK characterization and screening


     


O Octet RED384 t R 4 Oc et Octet QK384 84





 


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80